Idelalisib: new targeted therapy improves outlook for patients with chronic lymphocytic leukaemia

Idelalisib: new targeted therapy improves outlook for patients with chronic lymphocytic leukaemia

User Photo
AudioMedica

6 years
1,623 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
NEW ORLEANSA new oral tyrosine kinase inhibitor drug idelalisib has proved effective and to have low toxicity in patients with chronic lymphocytic leukaemia (CLL). Richard Furman MD from Weill Cornell Medical College in New York announced findings at the American Society of Hematology Annual Meeting of a phase III, double blind, placebo-controlled study randomising patients to have idelalisib or placebo added to their rituximab treatment. He discussed the clinical implications with AudioMedica.com of the extension of both progression-free and overall survival among patients receiving the new agent in comparison with placebo. Jennifer Brown MD PhD, Director of the Chronic Lymphocytic Leukemia Center at the Dana-Farber Cancer Institute in Boston added her comments and explained why she considered idelalisib is a good candidate for early approval. CONTACT: Dr. Richard Furman MD SOURCE: Abstract LBA 6 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL) LINK: https://ash.confex.com/ash/2013/webprogram/Paper66044.html
Up Next Autoplay
User Photo